|
Maharashtra, particularly the Mumbai-Pune corridor, is indisputably the powerhouse of the Indian pharmaceutical industry. Contributing approximately 25-30 per cent of India’s total pharmaceutical output and housing over 40 per cent of the nation’s pharmaceutical R&D centres, the state is a critical hub for manufacturing, innovation, and exports. However, this pre-eminent position is challenged by intense domestic competition, infrastructural bottlenecks, environmental concerns, and a rapidly evolving global regulatory landscape.
Region-wise distribution of pharma industry
The pharmaceutical industry in Maharashtra is strategically concentrated in key regional clusters, each with a distinct role. The Mumbai Metropolitan Region (MMR), encompassing Mumbai, Thane, Navi Mumbai, and Palghar, remains the historical and corporate heartland.
It hosts the headquarters of industry giants like Cipla, Sun Pharma, and multinational corporations such as Pfizer and GSK, serving as a central hub for corporate functions, regulatory affairs, marketing, and R&D. While still a dominant centre for formulating complex drugs and vaccines, its high operational costs and space constraints are gradually shifting manufacturing focus to other regions.
According to the Maharashtra Industrial Development Corporation (MIDC), the Mumbai and Konkan region continues to account for a significant, though dynamically changing, portion of the state’s pharmaceutical units.
In contrast, Pune has solidified its status as the emerging “Pharma & Biotech Capital” of India. The region, including Pune city, Pimpri-Chinchwad, and Hinjawadi, is an epicentre of innovation, hosting a dense cluster of R&D centres, CRAMS players, and biotech startups, bolstered by world-class institutions like the National Chemical Laboratory and the Serum Institute of India. A report by the India Brand Equity Foundation (IBEF) highlights its prominence, noting over 800 manufacturing units in the broader region.
Meanwhile, Aurangabad is being developed as a focused manufacturing and export hub, with key areas like Aurangabad Industrial City (AURIC) benefiting from its designation as a Smart City and a node of the Delhi-Mumbai Industrial Corridor (DMIC).
The DMIC Trust reports significant investment commitments here for bulk drugs and formulations. Other notable clusters include Nashik, known for formulations and medical devices, and Nagpur & Amravati, which are emerging as important centres for pharmaceutical education and smaller-scale manufacturing, leveraging their central location and cost advantages.
Sector-wise distribution
Maharashtra’s pharmaceutical sector is remarkably diverse and vertically integrated, dominated by its world-leading production of formulations—including tablets, capsules, injectables, and ointments—with major centres in the Mumbai Metropolitan Region (MMR) and Pune.
While China remains the global leader in Active Pharmaceutical Ingredients (APIs), there is a strategic push under the Production Linked Incentive (PLI) scheme to boost domestic API manufacturing, with active units located in Aurangabad and Raigad.
Pune stands as the undisputed leader in biotechnology and vaccines, driven by giants like the Serum Institute of India and Gennova Biopharmaceuticals, making it the fastest-growing sector, supported by a thriving ecosystem of biotech startups.
The Contract Research and Manufacturing Services (CRAMS) segment is rapidly expanding, with companies in Pune and MMR offering end-to-end services from drug discovery and clinical trials to manufacturing for global innovators.
Furthermore, Pune is a top national hub for Clinical Research Organizations (CROs) and Pharmacovigilance (PV), leveraging its high density of hospitals, medical colleges, and IT talent for data management and clinical trial coordination.
The Knowledge Process Outsourcing (KPO) sector, including medical coding and billing, is concentrated in metropolitan areas like Mumbai, Pune, and Nagpur, capitalizing on the available skilled, English-speaking workforce to service US and European healthcare providers.
Growth opportunities & “hot points”
Maharashtra’s pharmaceutical industry is poised to capitalize on several high-growth opportunities, driven by global trends and its inherent strengths. The impending global patent cliff for biologics presents a massive opportunity in biosimilars and biologics, a sector where Maharashtra, with its strong biotech base concentrated in Pune, is perfectly positioned to become a global leader in development and manufacturing.
Concurrently, the development of complex generics-such as long-acting injectables and transdermal patches-offers a strategic avenue for higher margins and reduced competition, leveraging the advanced R&D expertise found in clusters like Pune.
Furthermore, the global shift towards outsourcing makes Contract Development and Manufacturing (CDMO) a rapidly expanding segment, for which Maharashtra’s existing manufacturing excellence and infrastructure make it a prime destination for international contracts.
Additional “hot points” for growth are found in adjacent sectors supported by strong government impetus and technological convergence. The government’s Production Linked Incentive (PLI) scheme provides significant tailwinds for the manufacturing of medical devices and diagnostics, an area with substantial potential for import substitution and export growth.
Perhaps most futuristically, the convergence of IT and biotechnology in urban hubs like Pune and Mumbai creates a fertile ground for innovation in Digital Health and HealthTech. This includes pioneering work in digital therapeutics, AI-driven drug discovery, and advanced health data analytics, positioning Maharashtra not just as a manufacturing powerhouse, but as a leading innovation ecosystem in the global life sciences landscape.
Hurdles and challenges
Maharashtra’s pharmaceutical sector faces significant operational hurdles, including infrastructure bottlenecks and environmental sustainability concerns. Traffic congestion, water scarcity, and an uneven power supply in key clusters increase the cost of doing business.
Furthermore, the industry’s water-intensive nature presents major ecological challenges, particularly in managing complex waste. A 2022 study highlighted the difficulty of treating wastewater laden with Active Pharmaceutical Ingredients (APIs), which threatens aquatic life, while the disposal of hazardous solid waste demands stringent adherence to pollution control board guidelines. These environmental issues necessitate substantial investment in treatment facilities and sustainable practices to mitigate their impact.
Beyond infrastructure and environmental pressures, the industry contends with regulatory, talent, and competitive challenges. Companies often experience delays in securing clearances from multiple agencies, despite a proactive state government.
A critical skilled labour shortage also exists; while there is no lack of graduates, a significant gap remains in industry-ready talent for niche fields like biologics manufacturing and advanced data science for clinical trials. Most pressingly, Maharashtra faces intense competition from other states such as Gujarat, Telangana, and Himachal Pradesh, which aggressively lure investment away with attractive incentives, modern infrastructure, and lower operational costs.
Govt initiatives to strengthen pharma ecosystem
The Government of Maharashtra, in collaboration with the Government of India, is implementing a multi-faceted strategy to strengthen the pharmaceutical ecosystem through attractive industrial policies and large-scale infrastructure development.
A cornerstone of this effort is the Maharashtra Industrial Policy, which provides significant incentives such as stamp duty and electricity duty exemptions, interest subsidies, and a special Megaproject Policy for investments exceeding a set threshold.
Complementing these financial benefits is the development of world-class industrial clusters, most notably AURIC (Aurangabad Industrial City), developed under the Delhi-Mumbai Industrial Corridor (DMIC) project. This initiative provides ready-to-occupy, plug-and-play infrastructure tailored for high-tech industries, including pharmaceuticals, thereby drastically reducing setup times and initial capital expenditure for
companies.
Further solidifying this supportive framework, the state is focused on enhancing self-reliance and streamlining regulatory processes. A key objective is the promotion of Bulk Drug Parks under the central Production Linked Incentive (PLI) Scheme for APIs, aiming to reduce the industry’s critical dependence on imported raw materials.
To accelerate business operations, the government has launched the MahaBiz Portal, a single-window clearance system that consolidates over 70 essential permissions and significantly expedites the process of establishing and running a business.
Moreover, the state is proactively assisting local industries in accessing and capitalizing on the benefits offered by the Government of India’s PLI Schemes for pharmaceuticals and medical devices, ensuring Maharashtra remains a competitive and attractive destination for pharmaceutical investment.
Taxation benefits
Unlike the IT sector, pharmaceutical manufacturing rarely qualifies for the direct tax benefits associated with Special Economic Zones (SEZs), as the nature of its processes makes such locations impractical. Consequently, the primary fiscal advantages for the industry are derived from the Maharashtra Industrial Policy, which offers indirect benefits such as stamp duty and electricity duty exemptions.
However, a significant direct tax incentive is available at the national level for research and development; under Section 35(2AB) of the Income Tax Act, companies can avail a weighted tax deduction of 150 per cent on in-house R&D expenses, providing a major advantage for innovative firms in hubs like Pune and Mumbai.
The road ahead
To retain its pre-eminent position, Maharashtra’s pharmaceutical sector must embrace a dual strategy focused on sustainable growth, beginning with the adoption of Green Pharma initiatives that mandate and incentivize Green Chemistry, zero-liquid discharge (ZLD) plants, and energy-efficient processes.
This environmental focus must be supported by developing specialized, cluster-based infrastructure in emerging regions like Aurangabad, featuring common effluent treatment plants (CETPs) and reliable utilities to reduce operational costs.
Furthermore, fostering deep industry-academia collaborations with institutions like Pune University and ICT Mumbai is crucial to develop tailored curricula and research in cutting-edge fields, while simultaneously promoting the adoption of Industry 4.0 technologies like AI and IoT is essential to enhance manufacturing efficiency, quality, and overall supply chain resilience.
Maharashtra’s pharmaceutical industry stands at a pivotal juncture. Its foundational strengths-a dense cluster of talent, capital, and institutions are formidable. However, to future-proof its dominance, the state must strategically address its infrastructural and environmental challenges while aggressively leveraging opportunities in biologics, CRAMS, and innovation.
Through sustained government support, industry commitment to sustainable practices, and a relentless focus on quality and innovation, Maharashtra is poised to not only remain the pharmacy of India but also to cement its status as a global life sciences and innovation hub.
(The author is Associate Professor, Shri Ganpati Institute of Pharmaceutical Sciences and Research, Tembhurni)
|